PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PSEUDOMONAS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,279 records · Page 71Linked to original sources

Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis.

We compared collagen shields hydrated in 1.36% tobramycin with topical 1.36% tobramycin for sustained treatment of experimental Pseudomonas keratitis in rabbits. Antibiotic therapy for a total of 24 hours was initiated 14 hours after an intrastromal injection of 10(3) logarithmic phase Pseudomonas aeruginosa. Seven groups were treated as follows: groups 1-3, collagen shields hydrated in tobramycin supplemented with topical 1.36% tobramycin drops at 4, 6, or 8 hour intervals; group 4, collagen shields hydrated in tobramycin without any further topical supplementation; group 5, topical tobramycin therapy, initially every half-hour for 4 hours, then hourly; group 6, collagen shields hydrated in balanced saline solution; and group 7, no treatment. Each group contained four eyes. The groups treated with collagen shields supplemented every 4 or 6 hours with topical tobramycin had significantly fewer colony forming units (CFU) than those receiving topical or collagen shield therapy alone (P < 0.001). The group treated with collagen shields hydrated in sterile saline had 10(7) CFU per cornea, which was not significantly different from the untreated group (P > 0.2). Collagen shields hydrated in tobramycin and supplemented with topical tobramycin were effective in sustained treatment of experimental Pseudomonas keratitis.

Animals↗

[Risk factors of pseudomonas infection in hemoblastosis patients].

A total of 67 patients with diseases of the blood system and infectious complications, admitted to the Hematological Department of the Novosibirsk Regional Clinical Hospital, were examined. For this study only patients with etiologically established diagnosis were taken. The study revealed that Pseudomonas sp., whose strains were susceptible to Ceftazidime in 100% of cases and resistant to Cefepime and Imipenem in 15-17% of cases, was the etiological agent of 13.6% of all cases of infectious complications in hemoblastosis patients. Infectious lesions of pulmonary parenchyma, the presence of chronic diseases of the respiratory tract in the medical history, neutropenia, artificial ventilation of the lungs were found to be adverse prognostic factors with respect to a high risk of Pseudomonas infection in such patients. Therapy with glucocorticosteroids and cytostatics, preceding antibacterial prophylaxis were not linked with the isolation of Pseudomonas from the patients exhibiting the same levels of lethality and severity of infectious complications.

Adolescent↗

Reduction in the adherence of Pseudomonas aeruginosa to human buccal epithelial cells with neuraminidase inhibition.

The aim of this study was to evaluate the reduction in the adherence of 33 strains of Pseudomonas aeruginosa isolated from humans and different animals to human buccal epithelial cells with neuraminidase inhibition. Buccal epithelial cells were incubated with strains of Pseudomonas aeruginosa in the presence or absence of the neuraminidase inhibitors, 2,3-dehydro-2-deoxy-N-acetyl-neuraminic acid (DANA) or N-acetyl-neuraminic acid (NANA). Incubation of cells with bacteria in the presence of either DANA or NANA reduced bacterial adherence significantly by 35.24 +/- 23.90%, and 68.00 +/- 22.51 %, respectively. We suggest that the in vivo effects of such interventions should be explored as potential mechanisms reducing Pseudomonas aeruginosa in the binding to buccal cells.

Animals↗

[Comparison of new giant bacteriophages OBP and Lu11 of soil pseudomonads with bacteriophages of phiKZ-supergroup of Pseudomonas aeruginosa].

Study of two recently isolated giant bacteriophages Lu11 and OBP that are active on Pseudomonas putida var. Manila and Pseudomonas fluorescens, respectively, demonstrated their similarity in morphology, genome size, and size of phage particles, with giant bacteriophages of Pseudomonas aeruginosa assigned to the supergroup of phiKZ-like phages of the family Myoviridae designated in this manner according to the best studied phage phiKZ that belongs to the species of this group widely distributed in nature. Comparison of major polypeptide sizes of mature particles suggests the similarity of certain proteins in the phages examined. In OBP particles visualized with an electron microscope, an "inner body" was detected, which points to the specific DNA package intrinsic to phages of phiKZ group. In the meantime, phages Lul11 and OBP do not exhibit resemblance among themselves or with any of earlier described phiKZ-like phages in respect to other traits; particularly, they have no detectable DNA homology. Note that phage Lu11 of P. putida var. Manila exhibits very slight homology with phage Lin68 of the family of P. aeruginosa phiKZ-like phages detected only in blot hybridization. This suggests the possible involvement of these phages in interspecies recombination ("gene shuffling") between phages of various bacterial species. Results of partial sequencing of phage genomes confirmed the phylogenetic relatedness of phage OBP to phages of the phiKZ-supergroup, whereas phage Lu11 most probably belongs to a novel species that is not a member of supergroup phiKZ composition. The results of the study are discussed in terms of the evolution of these phages.

Genome, Viral↗

Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.

Pseudomonas exotoxin (PE) is a 66,000 molecular weight protein secreted by Pseudomonas aeruginosa. PE is made up of three domains, and PE40 is a form of PE which lacks domain Ia (amino acids 1-252) and has very low cytotoxicity because it cannot bind to target cells. The sequence Arg-Glu-Asp-Leu-Lys (REDLK) at the carboxyl terminus of Pseudomonas exotoxin has been shown to be important for its cytotoxic activity (Chaudhary, V. K., Jinno, Y., FitzGerald, D. J., and Pastan, I. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 308-312). In this study, we tested the effect of altering the carboxyl sequence of PE from REDLK to the characteristic endoplasmic reticulum retention sequence, KDEL, or to KDEL repeated three times (KDEL)3. We also made similar changes at the carboxyl terminus of two chimeric toxins in which domain I of PE (amino acids 1-252) was either replaced with transforming growth factor alpha (TGF alpha) to make TGF alpha-PE40 or with a single chain antibody (anti-Tac) reacting with the human interleukin 2 receptor to make anti-Tac(Fv)-PE40. Statistical analyses of our results demonstrate that PE and its derivatives ending in KDEL or (KDEL)3 are significantly more active than PE or derivatives ending in REDLK. We have also found that brefeldin A, which is known to perturb the endoplasmic reticulum, inhibits the cytotoxic action of PE. Our results suggest that the altered carboxyl terminus may enable the toxin to interact more efficiently with a cellular component involved in translocation of the toxin to the cytosol.

ADP Ribose Transferases↗

[Severe lesions of the petrous bone caused by pseudomonas aeruginosa].

Pseudomonas aeruginosa is often isolated in infections of the ear cleft. In some circumstances, this organism can cause serious petrous or peri-petrous lesions. Two pictures are seen: Malignant external otitis with severe headaches, signs of external otitis, and usually pseudomonas aeruginosa is isolated. This is usually seen in an elderly diabetic patient. Nerve paralysis is the main risk. The other complications, very grave in the past, are rare nowadays with the use of selective antibiotic treatment. Pseudomonas aeruginosa is also the causative organism in extensive osteitis of the skull base. Diagnostic problems are seen in case of specific infections or tumoral lesions. The treatment includes the same medications as for the malignant external otitis, as well as complete surgical excision.

Aged↗

[Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].

Three preparations, viz. sheep serum for local application ("Sanoserum"), anti-Pseudomonas sheep immunoglobulin for passive immunization ("Immunoglobulin Pseudomonas") and Pseudomonas vaccine for active immunization ("Pseudovac"), have been obtained at the Central Laboratory of Sera and Vaccines in Warsaw, Poland. The laboratory study and clinical trial of these preparations have been carried out. The preparations have proved to be effective as supplement to the conventional methods for the early diagnosis and treatment of P. aeruginosa infection in burn patients.

Adult↗

[Use of pseudomonas immunoglobulin. Indications and results].

In comparison with polyvalent immunoglobulins, Pseudomonas immunoglobulin (Psomaglobin) is enriched several times in antibodies to Ps. lipopolysaccharide antigens and exotoxin A as well as lipid A. The resulting protective action which is superior to polyvalent immunoglobulins in infections with Pseudomonas, was demonstrated both in cell culture (protection against cytotoxicity of Ps. exotoxin A in heart muscle cells) and in animal models of sepsis. In patients suffering from Ps. pneumonia and Ps.-sepsis clinical improvement is seen after application of this immunoglobulin and also in quantifiable by scoring systems, the unequivocal proof of lowering lethality by using this specific immunoglobulin in Pseudomonas infection is to be shown however.

Critical Care↗

Pseudomonas exotoxin: chimeric toxins.

Pseudomonas exotoxin binds to and enters cells by receptor-mediated endocytosis. Within the cell it requires exposure to low pH to enable it to translocate to the cell cytoplasm where it inhibits protein synthesis by ADP-ribosylating elongation factor 2. The toxin has three main structural domains whose functions are: Ia, cell binding; II, translocation; and III, ADP-ribosylation. Key amino acids have been identified within each domain that are required for the function of the toxin. Chimeric toxins were made originally by using chemical cross-linking reagents to couple Pseudomonas exotoxin (or other toxins) to cell-binding proteins. More recently, a variety of Pseudomonas exotoxin-related chimeric toxins have been made by gene fusion technology. These chimeric toxins may be useful clinically for treating various diseases and experimentally for understanding receptor function.

ADP Ribose Transferases↗

[Development of resistance in imipenem therapy in Pseudomonas aeruginosa].

8.4% of the isolated Pseudomonas aeruginosa strains were resistant against imipenem in this study. 3.7% of them became resistant as a result of the antibiotic therapy. In some patients on intensive care units, the resistance of Pseudomonas aeruginosa against imipenem emerged within a few days. In two of these cases a simultaneous loss of activity of the other pseudomonas-beta-lactams was observed.

Cilastatin↗

In vivo effect of aminoglycoside on Pseudomonas aeruginosa in experiment.

In artificial pseudomonas infections undertaken on white mice the effectiveness of the aminoglycosides (gentamicin, tobramycin, netilmicin, amikacin) was compared. The most effective drugs on highly susceptible Ps. aeruginosa were amikacin and netilmicin. Moreover amikacin is probably capable of inhibiting pseudomonas toxin production. Therefore this preparation should be left in reserve for the treatment of serious pseudomonas processes.

Amikacin↗

The use of monoclonal antibodies in the diagnosis of partially treated Pseudomonas aeruginosa meningitis: patient report.

The objective of this study was to evaluate the efficacy of mouse anti-pseudomonas monoclonal antibodies to detect small numbers of pathogenic pseudomonas in the spinal fluid of a patient who had been treated with antibiotics for meningitis. Anti-605 monoclonal antibody against Pseudomonas aeruginosa PAC 605, a rough mutant, showed sensitivity similar to that of anti-Fisher 1 monoclonal antibody in detecting P. aeruginosa Fisher 1 antigens in boiled spinal fluid drawn from a patient with a P. aeruginosa perispinal abscess and partially treated meningitis.

Anti-Bacterial Agents↗

Anti-pseudomonas activity of anti-lipopolysaccharide hyperimmune equine plasma.

Passive immunotherapy with anti-lipopolysaccharide hyperimmune equine plasma (Anti-LPS) is effective in treating experimental Gram-negative bacterial infections. The bactericidal activity of anti-LPS towards five different Pseudomonas species, including two multiresistant Pseudomonas aeruginosa isolates was tested here, as well as the ability of anti-LPS to inhibit the quantitative chromogenic limulus amoebocyte lysate (LAL) assay. Anti-LPS caused a mean reduction of 84.4 +/- 3.2% (P less than 0.001) in the number of colony forming units (cfu) of all isolates, whereas saline and complement inactivated anti-LPS induced no reduction. Nonimmune control plasma caused a small reduction in % cfu but much less than anti-LPS hyperimmune plasma (13.5% vs 84.4%, P less than 0.001). In order to cause 99% inhibition of the LAL test of 5 ng/ml Pseudomonas aeruginosa LPS, IgG antibodies were required in 10(5)-fold excess. These results suggest that anti-LPS has potential in the therapy and prophylaxis of Gram-negative bacterial infections, especially where LPS is involved in the disease process.

Animals↗

Mucoid strains of Pseudomonas aeruginosa are devoid of mannuronan C-5 epimerase.

Mucoid strains of Azotobacter vinelandii, Pseudomonas aeruginosa and Pseudomonas syringae var glycinia synthesize alginate, an extracellular copolymer comprising D-mannuronosyl and L-guluronosyl moieties. Extracellular mannuronan C-5 epimerase, which converts polymannuronate to alginate, was demonstrated in supernatant fluid from cultures of A. vinelandii. However, the enzyme could not be demonstrated, using the same assay, in supernatant fluids of cultures of mucoid strains of P. aeruginosa or of P. syringae var glycinia, or in cell-free sonic extracts of P. aeruginosa. The results suggest that the pathways of alginate biosynthesis in A. vinelandii and Pseudomonas species may differ.

Alginates↗

[Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].

Activity of six quinolones (nalidixic acid, pipemidic acid, oxolinic acid, pefloxacin, ofloxacin and norfloxacin) against one-hundred and ten Pseudomonas strains was studied in vitro. Five species of Pseudomonas were represented, i.e. aeruginosa, maltophilia, cepacia, stutzeri and paucimobilis. Isolates came from two Paris hospitals. Minimal inhibitory concentrations (MICs) were determined using gelose dilution according to WHO recommendations (Mueller Hinton medium, multiple inoculator, controlled inoculum). Modal CMIs classify activities of the six tested quinolones against P. aeruginosa in the following order: nalidixic acid: 64 mg/l; pipemidic acid: 16-32 mg/l; oxolinic acid: 16 mg/l; pefloxacin: 2 mg/l; ofloxacin: 2 mg/l; norfloxacin: 1 mg/l. The other Pseudomonas species exhibit a variety of resistance phenotypes which are described in detail. High CMIs are found for certain P. aeruginosa strains. Two of these, i.e. DL 55 and DL 59, are highly resistant to all the tested quinolones. Their pattern of resistance is comparable to that of a mutant, PAO 38-02, obtained in vitro in the presence of pefloxacin. This fact suggests that quinolones may induce in vivo selection of resistant P. aeruginosa mutants.

Drug Resistance, Microbial↗

[Use of azlocillin in the treatment of Pseudomonas bronchopulmonary infections].

Eleven patients with severe bronchopulmonary infection due to Pseudomonas were treated with azlocillin in doses of 250 mg/kg/day. Severe preexisting respiratory diseases, such as bronchopulmonary carcinoma, bronchiectasis or respiratory insufficiency were present in all cases. All patients had been unsuccessfully treated with various antibiotics before they received azlocillin. The pathogenicity of the isolates was assessed by germ counts in sputum. Comparative in vitro sensitivities to carbenicillin and azlocillin were determined by the disc method and by measurement of the minimum inhibitory concentrations in liquid medium. All strains of Pseudomonas aeruginosa isolated were sensitive to azlocillin with minimum inhibitory concentrations of 0.5 to 64 micrograms/ml. When tested against carbenicillin, 4 of the strains were resistant and 1 had intermediate sensitivity. The carbenicillin/azlocillin minimum inhibitory concentrations ratio was usually equal to 4. Clinical results were satisfactory in 7 cases; inadequate response or failure was observed in 4 cases and attributed to the replacement of Pseudomonas by another pathogen (Proteus morganii or Klebsiella pneumoniae). This study suggests that azlocillin is of value in the treatment of bronchopulmonary infections caused by Ps. aeruginosa.

Adult↗

Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.

An in vivo model of Pseudomonas aeruginosa sepsis was developed with normal and neutropenic guinea pigs injected intravenously with a strain of Pseudomonas demonstrated in vitro to be synergistically susceptible to ticarcillin and tobramycin. Therapy with ticarcillin, tobramycin, or a combination of the two starting 4 hr after intravenous injection of microorganisms was administered every 2 hr for periods up to 40 hr. Each therapy was associated with significant reductions in bacterial counts in blood, liver, spleen, and kidney compared with untreated animals. In no tissue in either normal or granulocytopenic animals did therapy with a combination of ticarcillin and tobramycin reduce bacterial counts significantly more effectively than did the better single antibiotic agent alone. These findings suggest that when ticarcillin and tobramycin are administered to animals at doses equivalent to therapeutic doses given in humans, a synergistic effect in reduction of bacterial counts in parenchymal organs and blood is not observed. These studies may help explain clinical reports in humans describing a lack of synergistic activity of combination antibiotic therapy in patients with Pseudomonas sepsis.

Animals↗

[Ultrastructural changes in Pseudomonas aeruginosa cells as affected by gentamycin in in vitro and in vivo experiments].

Morphological changes in phagocytosed cells of Pseudomonas aeruginosa under the effect of gentamicin were studied with electron microscopy using ultrathin slices. Peritoneal macrophages induced by irritation of the peritoneum with medium 199 followed by inoculation with a 1-milliard suspension of Pseudomonas aeruginosa were used. Gentamicin was administered intramuscularly in single doses of 10, 20 and 50 mg/kg. The effect of gentamicin was also studied in vitro. The in vitro studies showed that gentamicin induced rarefaction of the cytoplasm in Pseudomonas aeruginosa, elimination of the nuclear material, formation of membrane structures and separation of the cytoplasmic membrane from the cell wall. The studies with exposure of phagocytosed bacteria to gentamicin showed that the phagocytosed bacterial cells had the most pronounced changes in their ultrastructure. Under the effect of gentamicin in a dose of 50 mg/kg there appeared 2 types of the cells with changes not observed in vitro. Investigation of the digestive capacity of phagocytes demonstrated that gentamicin favoured an increase in the phagocytic activity and digestive capacity.

Animals↗